70
Participants
Start Date
January 31, 2014
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
Olaparib
Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
Placebo
3 100mg tablets to be administered twice a day with approximately 240ml of water
Blackpool Victoria Hospital, Blackpool
Bradford Royal Infirmary, Bradford
Queen's Hospital, Burton-on-Trent
Velindre Cancer Centre, Cardiff
University Hospitals Coventry and Warwickshire NHS Trust, Coventry
Derby Teaching Hospitals NHS Foundation Trust, Derby
Beatson West of Scotland Cancer Centre, Glasgow
Withybush General Hospital, Haverfordwest
Huddersfield Royal Infirmary, Huddersfield
University Hospitals of Morecambe Bay, Lancashire
St James University Hospital, Leeds
Leicester Royal Infirmary, Leicester
Charing Cross Hospital, London
The Christie NHS Foundation Trust, Manchester
The James Cook University Hospital, Middlesbrough
Royal Preston Hospital, Preston
Weston Park Hospital, Sheffield
University Hospitals of North Midlands, Stoke-on-Trent
Singleton Hospital, Swansea
Wrexham Maelor Hospital, Wrexham
Collaborators (1)
AstraZeneca
INDUSTRY
Lisette Nixon
OTHER_GOV